Montelukast as a Controller of Atopic Syndrome

Phase 4CompletedNCT00559546

University of Helsinki61 enrolled

Overview

The purpose of the study is to find out if montelukast can be used to treat the various symptoms of allergic syndrome.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Seasonal Allergic Rhinitis Allergic Conjunctivitis Atopic Eczema Asthma

Interventions

montelukastDRUG

10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner

Eligibility

Sex: ALLMin age: 18 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Wheal diameter at least 4 mm in skin-prick test for both birch and timothy * Allergic symptoms in both upper airways (allergic rhinitis) and lower airways (asthma-like symptoms or diagnosed asthma) and at least one of the following: * Allergic conjunctivitis * Atopic eczema * Oral symptoms from vegetables or fruits by cross reactivity to birch * Urticaria in allergen exposure Exclusion Criteria: * Need for regular treatment with glucocorticoids * Current smoking * Other major disease or need for regular drug treatment * Pregnancy

Locations (1)

Skin and Allergy Hospital, Helsinki University Hospital

Helsinki, Finland

Outcomes

Primary Outcomes

Allergic symptoms

Time frame: 3 weeks

Secondary Outcomes

Need for antihistamines or inhaled beta-2-agonists to relieve symptoms

Time frame: 3 weeks

Exhaled nitric oxide concentration

Time frame: 3 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.